Cargando…

Expression of p53 protein isoforms predicts survival in patients with multiple myeloma

Loss and/or mutation of the TP53 gene are associated with short survival in multiple myeloma, but the p53 landscape goes far beyond. At least 12 p53 protein isoforms have been identified as a result of a combination of alternative splicing, alternative promoters and/or alternative transcription site...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rojas, Elizabeta A., Corchete, Luis A., De Ramón, Cristina, Krzeminski, Patryk, Quwaider, Dalia, García‐Sanz, Ramón, Martínez‐López, Joaquín, Oriol, Albert, Rosiñol, Laura, Bladé, Joan, Lahuerta, Juan José, San Miguel, Jesús F., González, Marcos, Mateos, María Victoria, Bourdon, Jean‐Christophe, Misiewicz‐Krzeminska, Irena, Gutiérrez, Norma C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313569/ https://www.ncbi.nlm.nih.gov/pubmed/35188691 http://dx.doi.org/10.1002/ajh.26507

Ejemplares similares

Factors Regulating microRNA Expression and Function in Multiple Myeloma
por: Misiewicz-Krzeminska, Irena, et al.
Publicado: (2019)

A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility
por: Misiewicz-Krzeminska, Irena, et al.
Publicado: (2018)

DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma
por: Quwaider, Dalia, et al.
Publicado: (2017)

Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background
por: Rojas, Elizabeta A., et al.
Publicado: (2019)

Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma
por: Herrero, Ana B., et al.
Publicado: (2016)

P848: EXPRESSION PROFILE OF BCL-2 FAMILY PROTEINS IN MULTIPLE MYELOMA.
por: Sánchez, Cristina De Ramón, et al.
Publicado: (2023)

FAM46C controls antibody production by the polyadenylation of immunoglobulin mRNAs and inhibits cell migration in multiple myeloma
por: Herrero, Ana Belén, et al.
Publicado: (2020)

RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation
por: Quwaider, Dalia, et al.
Publicado: (2022)

Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome
por: De Ramón, Cristina, et al.
Publicado: (2022)

Effect of Graphene Family Materials on Multiple Myeloma and Non-Hodgkin’s Lymphoma Cell Lines
por: Strojny, Barbara, et al.
Publicado: (2020)

Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138(++) and CD138(low) Subpopulations in Multiple Myeloma Cell Lines
por: Paíno, Teresa, et al.
Publicado: (2014)

Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse
por: Krzeminski, Patryk, et al.
Publicado: (2016)

Extracellular Vesicles in Multiple Myeloma—Cracking the Code to a Better Understanding of the Disease
por: Iskrzak, Justyna, et al.
Publicado: (2022)

Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial
por: Puig, Noemí, et al.
Publicado: (2020)

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
por: Medina, Alejandro, et al.
Publicado: (2020)

Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair
por: López-Iglesias, Ana-Alicia, et al.
Publicado: (2017)

The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma
por: Hernández-García, Susana, et al.
Publicado: (2017)

CRL4(CRBN) E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma
por: Barankiewicz, Joanna, et al.
Publicado: (2022)

Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group
por: Mosquera Orgueira, Adrian, et al.
Publicado: (2022)

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials
por: Lopez-Anglada, Lucia, et al.
Publicado: (2018)

NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial
por: Rosa-Rosa, Juan Manuel, et al.
Publicado: (2022)

Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma
por: Puig, Noemí, et al.
Publicado: (2021)

Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma
por: Puig, Noemí, et al.
Publicado: (2022)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
por: Rosiñol, Laura, et al.
Publicado: (2023)

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients
por: Medina, Alejandro, et al.
Publicado: (2020)

P846: EXPRESSION SIGNATURE OF TP53 BIALLELIC INACTIVATION IDENTIFIES A GROUP OF MULTIPLE MYELOMA PATIENTS WITHOUT THIS GENETIC CONDITION BUT WITH DISMAL OUTCOME.
por: De Ramón, C., et al.
Publicado: (2022)

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
por: Rodríguez-Otero, Paula, et al.
Publicado: (2019)

Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma
por: Martinez-Lopez, J, et al.
Publicado: (2017)

Decytabine enhances cytotoxicity induced by oxaliplatin and 5-fluorouracil in the colorectal cancer cell line Colo-205
por: Flis, Sylwia, et al.
Publicado: (2009)

Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma
por: Algarín, Esperanza M., et al.
Publicado: (2021)

Randomized phase II study of weekly carfilzomib 70 mg/m(2) and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients
por: Puertas, Borja, et al.
Publicado: (2023)

Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations()
por: Lopez, Aurelio, et al.
Publicado: (2015)

The CRBN, CUL4A and DDB1 Expression Predicts the Response to Immunomodulatory Drugs and Survival of Multiple Myeloma Patients
por: Barankiewicz, Joanna, et al.
Publicado: (2021)

Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution
por: Jiménez-Segura, Raquel, et al.
Publicado: (2022)

A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
por: Encinas, Cristina, et al.
Publicado: (2022)

Measurable residual disease in multiple myeloma: ready for clinical practice?
por: Burgos, Leire, et al.
Publicado: (2020)

Extramedullary disease in multiple myeloma: a systematic literature review
por: Bladé, Joan, et al.
Publicado: (2022)

P878: SELINEXOR IN COMBINATION WITH DARATUMUMAB-BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF RELAPSE OR REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS OF THE PHASE 2, MULTICENTER GEM-SELIBORDARA STUDY
por: Gonzalez-Calle, Veronica, et al.
Publicado: (2023)

Systematic comparison and assessment of RNA-seq procedures for gene expression quantitative analysis
por: Corchete, Luis A., et al.
Publicado: (2020)

Multiple myeloma with t(11;14): impact of novel agents on outcome
por: Puertas, Borja, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_je0ukh9vc3ctgbgu85h8cgo7ju